Compare · ESPR vs LLY
ESPR vs LLY
Side-by-side comparison of Esperion Therapeutics Inc. (ESPR) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESPR and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 1334.6x ESPR ($810.9M).
- Over the past year, ESPR is up 160.6% and LLY is up 47.9% - ESPR leads by 112.7 points.
- LLY has been more active in the news (17 items in the past 4 weeks vs 11 for ESPR).
- Both have 25 recent analyst ratings on file.
- Company
- Esperion Therapeutics Inc.
- Eli Lilly and Company
- Price
- $3.14-0.16%
- $1143.94-0.51%
- Market cap
- $810.9M
- $1.08T
- 1M return
- +0.00%
- +20.60%
- 1Y return
- +160.58%
- +47.88%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- News (4w)
- 11
- 17
- Recent ratings
- 25
- 25
Esperion Therapeutics Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ESPR
- SEC Form 8-K filed by Esperion Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.
- SEC Form DEFM14A filed by Esperion Therapeutics Inc.
- Director Thompson John Craig was granted 79,873 shares (SEC Form 4)
- Director Shepard Jay was granted 79,873 shares, increasing direct ownership by 94% to 164,472 units (SEC Form 4)
- Director Hoffman Robert E. was granted 79,873 shares, increasing direct ownership by 1,513% to 85,153 units (SEC Form 4)
- Director Fischer Seth H. Z. was granted 79,873 shares, increasing direct ownership by 131% to 141,023 units (SEC Form 4)
- Director Carroll J Martin was granted 79,873 shares, increasing direct ownership by 82% to 177,523 units (SEC Form 4)
- Esperion Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form PREM14A filed by Esperion Therapeutics Inc.
Latest LLY
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
- Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
- Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications
- Lilly's Cancer Bombshell Sparks Hunt for the Next Oncology Stock Set to Explode
- Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care
- Foundayo and Zepbound now covered for millions of Americans
- Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference
- Lilly announces three acquisitions to build infectious disease portfolio
- A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets